136 related articles for article (PubMed ID: 32229418)
1. Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors.
Romanski NA; Holmstroem RB; Ellebaek E; Svane IM
Eur J Cancer; 2020 May; 130():211-218. PubMed ID: 32229418
[TBL] [Abstract][Full Text] [Related]
2. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series.
Tew A; Khoja L; Pallan L; Steven N
J Oncol Pharm Pract; 2023 Jul; 29(5):1163-1171. PubMed ID: 35607278
[TBL] [Abstract][Full Text] [Related]
3. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases.
Robin TP; Breeze RE; Smith DE; Rusthoven CG; Lewis KD; Gonzalez R; Brill A; Saiki R; Stuhr K; Gaspar LE; Karam SD; Raben D; Kavanagh BD; Nath SK; Liu AK
J Neurooncol; 2018 Oct; 140(1):55-62. PubMed ID: 29909499
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
Kothapalli A; Khattak MA
Melanoma Res; 2018 Apr; 28(2):155-158. PubMed ID: 29406396
[TBL] [Abstract][Full Text] [Related]
7. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.
Bernardo SG; Moskalenko M; Pan M; Shah S; Sidhu HK; Sicular S; Harcharik S; Chang R; Friedlander P; Saenger YM
Melanoma Res; 2013 Feb; 23(1):47-54. PubMed ID: 23262440
[TBL] [Abstract][Full Text] [Related]
8. Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events.
Araujo DV; Muniz TP; Yang A; Keshavarzi S; Sorotsky H; Butler MO; Saibil S; Spreafico A; Hogg D
Curr Oncol; 2021 Jun; 28(3):2173-2179. PubMed ID: 34208089
[TBL] [Abstract][Full Text] [Related]
9. Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion.
Ruini C; Haas C; Mastnik S; Knott M; French LE; Schlaak M; Berking C
J Immunother; 2021 Feb-Mar 01; 44(2):71-75. PubMed ID: 33323872
[TBL] [Abstract][Full Text] [Related]
10. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
12. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
13. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors.
Patrinely JR; McGuigan B; Chandra S; Fenton SE; Chowdhary A; Kennedy LB; Mooradian MJ; Palmeri M; Portal D; Horst SN; Scoville EA; Long GV; Shi C; Mehnert JM; Sullivan RJ; Salama AK; Sosman JA; Menzies AM; Johnson DB
Oncoimmunology; 2021 Feb; 10(1):1875639. PubMed ID: 33628621
[TBL] [Abstract][Full Text] [Related]
14. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
Del Castillo M; Romero FA; Argüello E; Kyi C; Postow MA; Redelman-Sidi G
Clin Infect Dis; 2016 Dec; 63(11):1490-1493. PubMed ID: 27501841
[TBL] [Abstract][Full Text] [Related]
15. Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal.
Gauci ML; Baroudjian B; Bédérède U; Zeboulon C; Delyon J; Allayous C; Madelaine I; Eftekhari P; Resche-Rigon M; Poté N; Paradis V; Durand F; Lebbé C; Roux O; Bouattour M;
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101491. PubMed ID: 32773362
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
17. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
20. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
